排序方式: 共有33条查询结果,搜索用时 15 毫秒
1.
Lalantha Leelarathna Pratik Choudhary Emma G. Wilmot Alistair Lumb Tim Street Partha Kar Sze M. Ng 《Diabetes, obesity & metabolism》2021,23(3):655-660
Hybrid closed-loop systems are characterized by the coexistence of algorithm-driven automated insulin delivery combined with manual mealtime boluses. Used correctly, these insulin delivery systems offer better glucose control and reduced risk of hypoglycaemia and represent the most advanced form of insulin delivery available for people with type 1 diabetes. The aim of this paper was to compare the currently available commercial hybrid closed-loop systems in the UK: the Medtronic 670G/780G, Tandem t:slim X2 Control IQ and CamAPS FX systems. The Medtronic 670G/780G systems use Guardian 3 sensor (7-day use, two to four calibrations per day), while Tandem and CamAPS systems use the calibration-free Dexcom G6 sensor (10 days). The CamAPS system is available as an android app, whereas the other two systems have the algorithm embedded in the insulin pump. During pivotal studies, depending on the study population and baseline glycated haemoglobin level, these systems achieve a time spent in the target range 3.9 to 10 mmol/L (70 to 180 mg/dL) of 65% to 76% with low burden of hypoglycaemia. All three systems allow a higher glucose target for announced exercise, while the Tandem system offers an additional night-time tighter target. The CamAPS system offers fully customizable glucose targets and is the only system licensed for use during pregnancy. Additional education is required for both users and healthcare professionals to harness the best performance from these systems as well as to troubleshoot when “automode exits” occur. We provide consensus recommendations to develop pragmatic pathways to guide patients, clinicians and commissioners in making informed decisions on the appropriate use of the diabetes technology. 相似文献
2.
Martin Tauschmann Hood Thabit Lalantha Leelarathna Daniela Elleri Janet M. Allen Alexandra Lubina-Solomon Marietta Stadler Emma Walkinshaw Ahmed Iqbal Pratik Choudhary Malgorzata E. Wilinska Simon R. Heller Stephanie A. Amiel Mark L. Evans David B. Dunger Roman Hovorka 《Journal of diabetes science and technology》2015,9(6):1346-1347
3.
Roman Hovorka Daniela Elleri Hood Thabit Janet M. Allen Lalantha Leelarathna Ranna El-Khairi Kavita Kumareswaran Karen Caldwell Peter Calhoun Craig Kollman Helen R. Murphy Carlo L. Acerini Malgorzata E. Wilinska Marianna Nodale David B. Dunger 《Diabetes care》2014,37(5):1204-1211
OBJECTIVE
To evaluate feasibility, safety, and efficacy of overnight closed-loop insulin delivery in free-living youth with type 1 diabetes.RESEARCH DESIGN AND METHODS
Overnight closed loop was evaluated at home by 16 pump-treated adolescents with type 1 diabetes aged 12–18 years. Over a 3-week period, overnight insulin delivery was directed by a closed-loop system, and on another 3-week period sensor-augmented therapy was applied. The order of interventions was random. The primary end point was time when adjusted sensor glucose was between 3.9 and 8.0 mmol/L from 2300 to 0700 h.RESULTS
Closed loop was constantly applied over at least 4 h on 269 nights (80%); sensor data were collected over at least 4 h on 282 control nights (84%). Closed loop increased time spent with glucose in target by a median 15% (interquartile range −9 to 43; P < 0.001). Mean overnight glucose was reduced by a mean 14 (SD 58) mg/dL (P < 0.001). Time when glucose was <70 mg/dL was low in both groups, but nights with glucose <63 mg/dL for at least 20 min were less frequent during closed loop (10 vs. 17%; P = 0.01). Despite lower total daily insulin doses by a median 2.3 (interquartile range −4.7 to 9.3) units (P = 0.009), overall 24-h glucose was reduced by a mean 9 (SD 41) mg/dL (P = 0.006) during closed loop.CONCLUSIONS
Unsupervised home use of overnight closed loop in adolescents with type 1 diabetes is safe and feasible. Glucose control was improved during the day and night with fewer episodes of nocturnal hypoglycemia. 相似文献4.
5.
Charlotte K. Boughton PhD Sara Hartnell BSc Hood Thabit PhD Tina Poettler David Herzig PhD Malgorzata E. Wilinska PhD Nicole L. Ashcroft BSc Judy Sibayan MPH Nathan Cohen MSc Peter Calhoun PhD Lia Bally PhD Julia K. Mader PhD Mark Evans MD Lalantha Leelarathna PhD Roman Hovorka PhD 《Diabetes, obesity & metabolism》2021,23(6):1389-1396
6.
Hood Thabit PhD Charlotte Boughton PhD Womba Mubita RN Jose Rubio RN Stuart Allen MSc Robert Heugh BSc Julia K. Mader MD Parth Narendran PhD Mark Evans MD Lalantha Leelarathna PhD Malgorzata E. Wilinska PhD Catherine Fullwood PhD Clifford Garratt MD Roman Hovorka PhD Martin K. Rutter MD 《Diabetes, obesity & metabolism》2024,26(3):1105-1109
7.
Winkley K Sallis H Kariyawasam D Leelarathna LH Chalder T Edmonds ME Stahl D Ismail K 《Diabetologia》2012,55(2):303-310
Aims/hypothesis
Depressive disorders are associated with mortality within 18 months of presentation of diabetic foot ulcers (DFU). The main aim of this study was to determine whether depressive disorder is still associated with increased mortality in people with their first foot ulcer at 5 years. 相似文献8.
Lalantha Leelarathna Hood Thabit Janet M. Allen Marianna Nodale Malgorzata E. Wilinska Kevin Powell Stephen Lane Mark L. Evans Roman Hovorka 《Journal of diabetes science and technology》2014,8(2):267-272
The objective was to assess the reliability of a novel automated closed-loop glucose control system developed within the AP@home consortium in adults with type 1 diabetes. Eight adults with type 1 diabetes on insulin pump therapy (3 men; ages 40.5 ± 14.3 years; HbA1c 8.2 ± 0.8%) participated in an open-label, single-center, single-arm, 12-hour overnight study performed at the clinical research facility. A standardized evening meal (80 g CHO) accompanied by prandial insulin boluses were given at 19:00 followed by an optional snack of 15 g at 22:00 without insulin bolus. Automated closed-loop glucose control was started at 19:00 and continued until 07:00 the next day. Basal insulin delivery (Accu-Chek Spirit, Roche) was automatically adjusted by Cambridge model predictive control algorithm, running on a purpose-built embedded device, based on real-time continuous glucose monitor readings (Dexcom G4 Platinum). Closed-loop system was operational as intended over 99% of the time. Overnight plasma glucose levels (22:00 to 07:00) were within the target range (3.9 to 8.0 mmol/l) for 75.4% (37.5, 92.9) of the time without any time spent in hypoglycemia (<3.9 mmol/l). Mean overnight glucose was 7.8 ± 1.3 mmol/l. For the entire 12-hour closed-loop period (19:00 until 07:00) plasma glucose levels were within the target range (3.9 to 10.0 mmol/l) for 84.4% (63.3, 100) of time. There were no adverse events noted during the trial. We observed a high degree of reliability of the automated closed-loop system. The time spent in target glucose level overnight was comparable to results of previously published studies. Further developments to miniaturize the system for home studies are warranted. 相似文献
9.